24/7 Market News Snapshot 16 October, 2025 – Artiva Biotherapeutics, Inc. Common Stock (NASDAQ:ARTV)

October 16, 2025

DENVER, Colo., 16 October, 2025 (www.247marketnews.com) – (NASDAQ:ARTV) are discussed in this article.
Artiva Biotherapeutics, Inc. has experienced a remarkable surge in its stock, with shares opening at $3.03 and skyrocketing to a high of $5.754, representing an impressive increase of 91.16%. This substantial market movement comes amidst strong trading volume of 3.59 million shares, indicating heightened investor confidence in the company’s innovative biotherapeutics. As Artiva continues to break through key resistance levels, investors are keenly watching developments, anticipating further gains as the firm progresses in its mission to redefine therapeutic solutions in healthcare.

In addition to this market excitement, Artiva has recently achieved a significant milestone with its lead therapeutic candidate, AlloNK®, receiving Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of refractory rheumatoid arthritis (RA). AlloNK® stands out as the first drug candidate within the deep B-cell depleting category to achieve this designation, emphasizing Artiva’s strategic focus on addressing the unmet needs of the estimated 100,000 individuals who remain resistant to existing RA therapies.

CEO Fred Aslan highlighted the importance of this designation, noting it represents a pivotal moment in their efforts to tackle a substantial healthcare challenge. With over 20 patients treated in various autoimmune disease trials, emerging data suggests AlloNK® achieves deep B-cell depletion effectively, enhancing the therapeutic potential of existing B-cell targeting antibodies.

Artiva plans to share initial safety and translational data in mid-November, along with clinical response data anticipated in the first half of 2026. The company’s commitment to innovation promises to deliver transformative therapies for patients battling autoimmune diseases, reinforcing its position as a leader in biotechnology advancements.

Related news for (ARTV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.